Literature DB >> 16150402

Management of "refractory" skin disease in patients with lupus erythematosus.

Jeffrey P Callen1.   

Abstract

Skin disease in patients with lupus erythematosus can be subdivided into two broad categories-those lesions that, when biopsied, demonstrate an interface dermatitis and those that do not demonstrate an interface dermatitis. The skin lesions that are represented by the interface dermatitis include discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and acute cutaneous lupus erythematosus. Many patients with these cutaneous lesions can be managed with "standard" therapies, including sunscreens, protective clothing and behavioral alteration, and topical corticosteroids with or without an oral antimalarial agent. These standard therapies are often not used appropriately, resulting in a situation in which the patient is felt to have refractory disease. This chapter discusses these therapies and defines what is meant by refractory disease and how the author approaches these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150402     DOI: 10.1016/j.berh.2005.05.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  7 in total

1.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

2.  [Cutaneous lupus erythematosus. Part 2: diagnostics and therapy].

Authors:  A Kuhn; K Gensch; S Ständer; G Bonsmann
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

3.  A case of "refractory" lupus erythematosus profundus responsive to rituximab [case report].

Authors:  Adrian McArdle; Joshua F Baker
Journal:  Clin Rheumatol       Date:  2009-04-03       Impact factor: 2.980

4.  In silico Analyses of Skin and Peripheral Blood Transcriptional Data in Cutaneous Lupus Reveals CCR2-A Novel Potential Therapeutic Target.

Authors:  Rama Dey-Rao; Animesh A Sinha
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

5.  Interventions for cutaneous disease in systemic lupus erythematosus.

Authors:  Cora W Hannon; Collette McCourt; Hermenio C Lima; Suephy Chen; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2021-03-09

6.  Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.

Authors:  Josefina Cortés-Hernández; Gabriela Ávila; Miquel Vilardell-Tarrés; Josep Ordi-Ros
Journal:  Arthritis Res Ther       Date:  2012-12-07       Impact factor: 5.156

7.  Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways.

Authors:  Sandra Domingo; Cristina Solé; Teresa Moliné; Berta Ferrer; Josefina Cortés-Hernández
Journal:  Biomedicines       Date:  2021-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.